Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.pneurobio.2016.07.004 http://scihub22266oqcxt.onion/10.1016/j.pneurobio.2016.07.004 C5362348!5362348!27519538     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Prog+Neurobiol 2017 ; 152 (ä): 3-20 Nephropedia Template TP {{tp|p=27519538|t=2017. NEW DRUG DEVELOPMENTS IN PSYCHOSIS: CHALLENGES, OPPORTUNITIES AND STRATEGIES |pdf=|usr=}}{{27519538}} gab.com Text NEW DRUG DEVELOPMENTS IN PSYCHOSIS: CHALLENGES, OPPORTUNITIES AND STRATEGIES JO: Prog Neurobiol http://www.kidney.de/pget.php?&tw=1&pmid=27519538 #FOAvip All currently approved drugs for schizophrenia work mainly by dopaminergic antagonism. While they are efficacious for psychotic symptoms, their efficacy is limited for negative symptoms and cognitive deficits which underlie the substantive disability in this illness. Recent insights into the biological basis of schizophrenia, especially in relation to non-dopaminergic mechanisms, have raised the efforts to find novel and effective drug targets, though with relatively little success thus far. Potential impediments to novel drug discovery include the continued use of symptom based disease definitions which leads to etiological and pathophysiological heterogeneity, lack of valid preclinical models for drug testing, and design limitations in clinical trials. These roadblocks can be addressed by (i) characterizing trans-diagnostic, translational pathophysiological dimensions as potential treatment targets, (ii) efficiency, accountability and , transparency in approaches to the clinical trials process, and (iii) leveraging recent advances in genetics and in vitro phenotypes. Accomplishing these goals is urgent given the significant unmet needs in the pharmacological treatment of schizophrenia. As this happens, it is imperative that clinicians employ optimal dosing, measurement-based care, and other best practices in utilizing existing treatments to optimize outcomes for their patients today. Twit Text FOAVip NEW DRUG DEVELOPMENTS IN PSYCHOSIS: CHALLENGES, OPPORTUNITIES AND STRATEGIES ????Prog Neurobiol http://www.kidney.de/pget.php?&tw=1&pmid=27519538 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27519538 #FOAvip English Wikipedia <ref>{{Cite pmid|27519538}}</ref> NEW DRUG DEVELOPMENTS IN PSYCHOSIS: CHALLENGES, OPPORTUNITIES AND STRATEGIES #MMPMID27519538 Keshavan MS; Lawler AN; Nasrallah HA; Tandon R Prog Neurobiol 2017[May]; 152 (ä): 3-20 PMID27519538show ga All currently approved drugs for schizophrenia work mainly by dopaminergic antagonism. While they are efficacious for psychotic symptoms, their efficacy is limited for negative symptoms and cognitive deficits which underlie the substantive disability in this illness. Recent insights into the biological basis of schizophrenia, especially in relation to non-dopaminergic mechanisms, have raised the efforts to find novel and effective drug targets, though with relatively little success thus far. Potential impediments to novel drug discovery include the continued use of symptom based disease definitions which leads to etiological and pathophysiological heterogeneity, lack of valid preclinical models for drug testing, and design limitations in clinical trials. These roadblocks can be addressed by (i) characterizing trans-diagnostic, translational pathophysiological dimensions as potential treatment targets, (ii) efficiency, accountability and , transparency in approaches to the clinical trials process, and (iii) leveraging recent advances in genetics and in vitro phenotypes. Accomplishing these goals is urgent given the significant unmet needs in the pharmacological treatment of schizophrenia. As this happens, it is imperative that clinicians employ optimal dosing, measurement-based care, and other best practices in utilizing existing treatments to optimize outcomes for their patients today. äNEW DRUG DEVELOPMENTS IN PSYCHOSIS: CHALLENGES, OPPORTUNITIES AND STRA(epmc).pdf DeepDyve Pubget Overpricing